PULSE BIOSCIENCES IN (PLSE) is drawing unusual attention today. Our newswire has captured 3 stories on PLSE across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Pulse Biosciences stock rose 8.17% to $35.47 in morning trading as Oppenheimer raised its price target for the company following the release of atrial fibrillation data. The move reflects renewed investor confidence in the company’s therapeutic development progress. The stock has traded within a 52-week range of $12.56 to $33.87, and the recent rally pushes it above its previous high.
Oppenheimer increased its price target for PLSE based on positive data from the company’s atrial fibrillation program. This upgrade follows recent insider purchases by the CEO and a director, who together bought approximately $13.3 million in shares through an ATM program on May 11. Additionally, Canaccord Genuity initiated coverage on Pulse Biosciences with a Buy rating and a $32 price target. These developments suggest growing institutional and internal support for the stock’s potential. Pulse Biosciences also reported first-quarter earnings of $(0.27) per share, which beat the estimated $(0.32), and revenue of $401,000, exceeding the forecast of $400,000.
The stock has traded with a beta of 1.65, indicating higher volatility than the broader market. Despite a market cap of $2.1 billion, the company remains unprofitable with a trailing twelve-month EPS of -1.10. Recent insider activity has been entirely in the form of purchases, with no sell transactions reported in the last 90 days. The stock’s 30-day average sentiment score is 61 out of 100, improving to 67 in the last seven days. This suggests a gradual shift in market perception.
Investors should look ahead to May 4, 2026, when the company is scheduled to report earnings. Coverage breadth will be a key factor to monitor as the stock continues to attract new institutional attention.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Pulse Biosciences ( ($PLSE) ) has issued an update. On July 29, 2026, Pulse Biosciences reported that its NANOPULSE-AF pivotal clinical study, which began in April ...
Filed: 2026-07-29 AccNo: 0001437749-26-024758 Size: 172 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
PULSE BIOSCIENCES IN (PLSE) is drawing unusual attention today. Our newswire has captured 3 stories on PLSE across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100). The most recent driver: "Pulse Biosciences advances NANOPULSE-AF pivotal study enrollment" (TipRanks).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of PLSE coverage reads 59/100 over 3 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on PLSE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PLSE move explainers: 2026-07-29 · 2026-07-28 · 2026-07-23 · 2026-07-22